Privia Health Group Inc (PRVA) valuation
Privia Health Group P/E ratio history
Privia Health Group trades at 97.6 times its earnings over the last twelve months and 22.0 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 121.2 (year to Dec 2023) to 177.7 (year to Dec 2024), with a median of 131.7.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $23.71 | $0.18 | 131.7 | — |
| Dec 31, 2024 | $19.55 | $0.11 | 177.7 | 85.6 |
| Dec 31, 2023 | $23.03 | $0.19 | 121.2 | 85.3 |
| Dec 31, 2022 | $22.71 | -$0.08 | n/m | — |
| Dec 31, 2021 | $25.87 | -$1.83 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Privia Health Group valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Privia Health GroupPRVA | $2.71B | 97.6 | 22.0 | 1.2 |
| Enliven TherapeuticsELVN | $2.69B | — | — | — |
| Mbx BiosciencesMBX | $2.66B | — | — | — |
| Dyne TherapeuticsDYN | $2.76B | — | — | — |
| AxogenAXGN | $2.65B | — | 73.6 | 9.9 |
| Adma BiologicsADMA | $2.65B | 16.3 | 13.1 | 5.2 |
| Nurix TherapeuticsNRIX | $2.78B | 11.7 | — | 4.0 |
| Beam TherapeuticsBEAM | $2.80B | — | — | 18.0 |
| Ideaya BiosciencesIDYA | $2.81B | — | — | 12.0 |
| Peer median | 14.0 | 43.3 | 9.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PRVA financials · PRVA returns
No forecast, no recommendation. This page describes Privia Health Group Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.